• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Boston Scientific

Where medtech is putting its money this November

October 17, 2018 By Nancy Crotti

Republicans reaped nearly $3.3 million in federal political contributions from the medtech industry in the 2017-18 election cycle, compared with $1.85 million for Democrats, according to data collected by the Center for Responsive Politics, a nonprofit campaign finance watchdog group. Medtech has “historically been a little more Republican than the average industry,” said Andrew Mayersohn, committees […]

Filed Under: Business/Financial News, Featured Tagged With: AdvaMed, Boston Scientific, centerforresponsivepolitics, Masimo, massmedic, medicalalley, medicaldevicemanufacturersassociation, Medtronic, starkeyhearingtechnologies

TCT 2018: Boston Scientific wins FDA nod for drug-eluting vascular stent

September 24, 2018 By Sarah Faulkner

Boston Scientific

On the heels of positive study results at the 30th Transcatheter Cardiovascular Therapeutics meeting, Boston Scientific (NYSE:BSX) won FDA approval for its drug-eluting vascular stent system, Eluvia. The device, which is designed for the treatment of peripheral artery disease, uses a drug-polymer combination to deliver paclitaxel over the course of a year. “Over the past decade, we’ve […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Vascular, Wall Street Beat Tagged With: abbott, biosensors, Biotronik, Boston Scientific, cook medical, Medtronic, TCT 2018

Boston Scientific launches trial for drug-eluting peripheral stent

September 10, 2018 By Sarah Faulkner

Boston Scientific

Boston Scientific (NYSE:BSX) said last week that it enrolled the first patient in a pivotal trial to evaluate its below-the-knee drug-eluting stent in patients with critical limb ischemia. The peripheral stent is the first of its kind to undergo the FDA’s breakthrough device program, according to the medtech giant. Roughly 17 million people in the U.S. […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Boston Scientific

RenovoRx sets its sights on localized treatment of pancreatic cancer

July 13, 2018 By Sarah Faulkner

RenovoRx updated logo

People living with pancreatic cancer find themselves facing devastating odds – the five-year survival rate is in the single digits, according to the American Cancer Rate. Pursuing treatment often means dealing with the side effects of systemic chemotherapy, including hair loss, fatigue and neuropathy. Shaun Bagai and his team at RenovoRx think that their catheter […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Oncology, Pharmaceuticals, Vascular Tagged With: Boston Scientific, Medtronic, RenovoRx

Biotronik touts two-year study comparing drug-eluting stents

May 25, 2018 By Sarah Faulkner

Biotronik yesterday presented two-year data from a trial comparing Boston Scientific‘s (NYSE:BSX) Synergy biodegradable polymer everolimus-eluting stent, Biotronik’s Orsiro sirolimus-eluting stent and Medtronic‘s (NYSE:MDT) Resolute Integrity zotarolimus-eluting stent. Results from the 3,514-patient trial showed no significant difference between the various stents regarding the rate of target vessel failure after two years. But analyses of one-year data found differences between the rates of […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Biotronik, Boston Scientific, Medtronic

EuroPCR 2018: Study compares drug-coated balloons in patients with arterial in-stent restenosis

May 23, 2018 By Sarah Faulkner

EuroPCR 2018

At this year’s annual EuroPCR meeting, Boston Scientific (NYSE:BSX touted results from the first trial to compare two drug-coated balloons with different drug formulations – Boston Scientific’s Agent paclitaxel-coated PTCA device and B. Braun’s SeQuent Please balloon. The 125-patient study evaluated the balloons in patients with in-stent restenosis of a lesion previously treated with a drug-eluting […]

Pages: Page 1 Page 2 Page 3 Page 4

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: amaranthmedical, B. Braun Medical, Boston Scientific, microportscientific

RenovoRx raises $7m for drug-device pancreatic cancer therapy

May 23, 2018 By Sarah Faulkner

RenovoRx

RenovoRx said today that it closed a $7 million tranche in a $10 million round to fund the development of its drug-device combination product designed to deliver chemotherapy directly to tumors in patients with locally advanced pancreatic cancer. The company’s round was led by Boston Scientific (NYSE:BSX) and joined by btov Partners, Astia Angels, Golden Seeds […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Oncology, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Boston Scientific, RenovoRx

Boston Scientific’s drug-coated balloon succeeds in femoropopliteal segment at one year

May 15, 2018 By Sarah Faulkner

Boston Scientific

Data from Boston Scientific‘s (NYSE:BSX) Ranger SFA trial showed that treatment with its drug-coated balloon succeeded in the femoropopliteal segment after one year and resulted in greater rates of patency, with fewer interventions, compared to standard balloon angioplasty. The results, which were published this month in JACC: Cardiovascular Interventions, demonstrated that both groups of patients – […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Boston Scientific

HRS 2018: Study questions benefit of ablation over drug therapy for atrial fibrillation

May 10, 2018 By Sarah Faulkner

HRS 2018

Long-awaited data released today from a large clinical trial comparing catheter ablation with drug therapy in treating atrial fibrillation showed no significant benefit for ablation, according to Dr. Douglas Packer, who presented the findings today at the annual meeting of the Heart Rhythm Society in Boston. The 2,204-patient trial, sponsored by the National Institutes of […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Biosense Webster, Boston Scientific, HRS 2018, Medtronic, St. Jude

Abbott pulls Xience Alpine drug-eluting stent from Indian market

April 27, 2018 By Sarah Faulkner

Abbott

Abbott (NYSE:ABT) reportedly stopped selling its Xience Alpine drug-eluting coronary stent in India this week in response to price caps set by the National Pharmaceutical Pricing Authority. A spokesperson for the healthcare firm said in a statement that Abbott “fulfilled all the requirements to discontinue selling its Xience Alpine drug-eluting stent in India as of April […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: abbott, Boston Scientific, Medtronic

  • « Go to Previous Page
  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to page 4
  • Go to page 5
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS